» Articles » PMID: 33087811

MicroRNA-941 Regulates the Proliferation of Breast Cancer Cells by Altering Histone H3 Ser 10 Phosphorylation

Overview
Journal Sci Rep
Specialty Science
Date 2020 Oct 22
PMID 33087811
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Breast cancer including triple negative breast cancer (TNBC) represents an important clinical challenge, as these tumours often develop resistance to conventional chemotherapeutics. MicroRNAs play a crucial role in cell-cycle regulation, differentiation, apoptosis, and migration. Herein, we performed Affymetrix Gene Chip miRNA 4.0 microarray and observed differential regulation of miRNAs (75 upregulated and 199 downregulated) in metastatic MDA-MB-231 cells as compared to immortalized human non-tumorigenic breast epithelial (MCF-10A) cells. MicroRNA-941 was significantly upregulated in MDA-MB-231 cells (almost nine-fold increase) in comparison to MCF-10A cells. Transfection of MiRNA-941 inhibitor significantly decreased the proliferation and migration of MDA-MB-231 cells by altering the expressions of p21, Cyclin D1, PP2B-B1, E-cadherin and MMP-13. Interestingly, we provide first evidence that inhibiting miR-941 prevents cell proliferation and phosphorylation of histone H3 at Ser10 residue. Xenograft model of breast cancer was developed by subcutaneous injection of MDA-MB-231 cells into the mammary fat pad of female athymic nude mice (Crl:NU-Foxn1nu). The tumours were allowed to grow to around 60 mm, thereafter which we divided the animals into seven groups (n = 5). Notably, intratumoral injection of miR-941 inhibitor significantly abolished the tumour growth in MDA-MB-231 xenograft model. 5-Fluorouracil (10 mg/kg, i.p.) was used as positive control in our study. To the best of our knowledge, we report for the first time that targeting miR-941 improves the sensitivity of MDA-MB-231 cells to 5-fluorouracil. This can be of profound clinical significance, as it provides novel therapeutic approach for treating variety of cancers (overexpressing miRNA-941) in general and breast cancers in particular.

Citing Articles

Micro RNA Dysregulation in Keratinocyte Carcinomas: Clinical Evidence, Functional Impact, and Future Directions.

Conley J, Genenger B, Ashford B, Ranson M Int J Mol Sci. 2024; 25(15).

PMID: 39126067 PMC: 11313315. DOI: 10.3390/ijms25158493.


The roles of histone modifications in tumorigenesis and associated inhibitors in cancer therapy.

Yang Y, Zhang M, Wang Y J Natl Cancer Cent. 2024; 2(4):277-290.

PMID: 39036551 PMC: 11256729. DOI: 10.1016/j.jncc.2022.09.002.


MiR-4646-5p Acts as a Tumor-Suppressive Factor in Triple Negative Breast Cancer and Targets the Cholesterol Transport Protein GRAMD1B.

Jonas K, Prinz F, Ferracin M, Krajina K, Deutsch A, Madl T Noncoding RNA. 2024; 10(1).

PMID: 38250802 PMC: 10801495. DOI: 10.3390/ncrna10010002.


Identification of differentially expressed genes associated with the pathogenesis of gastric cancer by bioinformatics analysis.

Abdolahi F, Shahraki A, Sheervalilou R, Mortazavi S BMC Med Genomics. 2023; 16(1):311.

PMID: 38041130 PMC: 10690994. DOI: 10.1186/s12920-023-01720-7.


Emerging roles of interactions between ncRNAs and other epigenetic modifications in breast cancer.

Xie J, Gan L, Xue B, Wang X, Pei X Front Oncol. 2023; 13:1264090.

PMID: 37901333 PMC: 10602744. DOI: 10.3389/fonc.2023.1264090.


References
1.
Nelson K, Weiss G . MicroRNAs and cancer: past, present, and potential future. Mol Cancer Ther. 2008; 7(12):3655-60. DOI: 10.1158/1535-7163.MCT-08-0586. View

2.
Garcia-Vazquez R, Ruiz-Garcia E, Meneses Garcia A, Astudillo-de la Vega H, Lara-Medina F, Alvarado-Miranda A . A microRNA signature associated with pathological complete response to novel neoadjuvant therapy regimen in triple-negative breast cancer. Tumour Biol. 2017; 39(6):1010428317702899. DOI: 10.1177/1010428317702899. View

3.
Zhang C, Du H . Screening key miRNAs for human hepatocellular carcinoma based on miRNA-mRNA functional synergistic network. Neoplasma. 2017; 64(6):816-823. DOI: 10.4149/neo_2017_602. View

4.
Baranwal S, Alahari S . miRNA control of tumor cell invasion and metastasis. Int J Cancer. 2009; 126(6):1283-90. PMC: 2950784. DOI: 10.1002/ijc.25014. View

5.
Ozawa K . Reduction of phosphorylated histone H3 serine 10 and serine 28 cell cycle marker intensities after DNA damage. Cytometry A. 2008; 73(6):517-27. DOI: 10.1002/cyto.a.20559. View